Test Price
2,700 AED✅ Home Collection Available
Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel in UAE | 2,700 AED | 2026 DHA Guidelines
تحليل لوحة الوراثيات الخلوية لسرطان الدم الليمفاوي الحاد (ALL) في الإمارات | 2700 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- ✓Guaranteed Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM daily).
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance with DHA-licensed hematologists for result interpretation.
- ✓Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
الملخص التنفيذي
يضمن مختبرنا المعتمد من هيئة الصحة بدبي دقة تشخيصية بنسبة 99.9% باستخدام تقنيات التهجين الموضعي المتألق (FISH) والتنميط النووي التقليدي، مع خدمة سحب منزلي متطورة واستشارات طبية بعد الفحص. جميع العينات تُنقل في سلسلة تبريد وفق معايير ISO 9001:2015 (شهادة INT/EGQ/2509DA/3139).
Clinical Overview / نظرة عامة سريرية
The Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel combines conventional karyotyping and FISH analysis on blood and bone marrow to detect specific chromosomal abnormalities such as t(9;22) (Philadelphia chromosome), t(12;21), and hyperdiploidy, which are critical for risk stratification and therapeutic decision-making in pediatric and adult ALL. تجمع هذه اللوحة بين التحليل النووي التقليدي وفحص FISH على عينات الدم ونخاع العظم للكشف عن تشوهات الكروموسومات الضرورية لتوجيه العلاج.
| Feature | Our Integrated Panel (FISH + Karyotyping) | Conventional Karyotyping Alone |
|---|---|---|
| Diagnostic Precision | Dual‑method resolution detects cryptic translocations missed by karyotyping alone | May miss microdeletions or low‑level mosaicism |
| Methodology | FISH (targeted probes) + full karyotype (G‑banding) on blood and bone marrow | G‑band karyotyping only, limited to dividing cells |
| Turnaround Time | 4 working days (expedited processing) | Typical 7–10 days |
| Clinical Utility | Full WHO‑2026 risk stratification, guides TKIs and HSCT decisions | Limited to large structural changes, insufficient for modern protocols |
2026 Medical Coding & Regulatory Compliance
- ICD‑10‑CM Codes (2026 Update): C91.0 (Acute lymphoblastic leukemia), Z15.02 (Genetic susceptibility to malignant neoplasm of lymphoid/hematopoietic tissue), C91.00 (ALL not having achieved remission).
- LOINC Code: 48801-6 – Leukemia/lymphoma cytogenetics panel – Blood or Bone marrow by FISH.
- Legal Mandates: Services strictly comply with Federal Decree‑Law No. 41 of 2024 (Art. 87), CDS Law 2026 governing minors, and UAE PDPL for sensitive health data. DHA Facility License: 9834453.
Physician Insight & Safety Protocol / رؤية الطبيب وبروتوكول السلامة
Clinical Note from Dr. Prabhakar Reddy, DHA 61713011: Cytogenetic findings are a vital component of the ALL diagnostic puzzle, yet they must always be correlated with morphological, immunophenotypic, and molecular data to frame a complete clinical picture. This panel equips your oncology team with the chromosomal roadmap needed for contemporary risk‑adapted therapy, including eligibility for tyrosine kinase inhibitors and haematopoietic stem cell transplantation. Our team is available to discuss results and their implications directly with you and your referring physician.
Safety & Exclusion Criteria
- Exclusion: Severe uncorrected coagulopathy (INR >1.5 or platelets <50,000/µL), active infection at the aspiration site.
- Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Anticoagulants may require temporary adjustment under specialist supervision.
- ER Red Flags: Post‑procedure excessive bleeding, new fever >38.5°C, or intense pain unresponsive to standard analgesia warrant immediate hospital evaluation.
Frequently Asked Questions / الأسئلة الشائعة
ما هي لوحة الوراثيات الخلوية لسرطان الدم الليمفاوي الحاد؟
The Acute Lymphoblastic Leukemia Cytogenetics Panel identifies chromosomal abnormalities in leukemia cells to guide prognosis and treatment. By employing both conventional karyotyping and FISH on blood and bone marrow, the test detects hallmark aberrations such as the Philadelphia chromosome (t(9;22)) and t(12;21), enabling precise risk stratification and therapy selection in accordance with 2026 WHO guidelines.
هل يلزم أخذ عينة من نخاع العظم؟
Yes, bone marrow sampling alongside blood is required for complete cytogenetic analysis in ALL. Bone marrow aspirate provides the optimal source of dividing leukemic cells for karyotyping, while peripheral blood can be used for FISH; the combination ensures a comprehensive cytogenetic profile. Our VIP home collection team performs both draws under stringent sterile conditions.
كيف يتم تفسير النتائج وهل أحتاج إلى استشارة طبية؟
Results are interpreted in correlation with clinical findings, and post-test teleconsultation is provided by our DHA-licensed hematologists. A comprehensive report details any detected chromosomal gains, losses, or translocations along with their prognostic significance. We strongly recommend scheduling the included post‑ clinical guidance to translate these findings into a personalised treatment strategy.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians